Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Evotec SE operates as a drug manufacturer specializing in the development of innovative therapeutics across various therapeutic areas, including oncology and neurology. The company has a strong presence in Europe and North America, leveraging its extensive drug discovery platform and partnerships with major pharmaceutical companies to drive its growth.
Evotec generates revenue primarily through long-term collaborations with pharmaceutical companies, providing drug discovery and development services. Its competitive advantage lies in its integrated platform that combines biology, chemistry, and data science, enabling faster and more efficient drug development processes.
New partnership announcements with major pharmaceutical companies
Progress in clinical trials for proprietary drug candidates
Changes in regulatory environment affecting drug approvals
Market trends in the biotech sector impacting investor sentiment
Regulatory changes that could delay drug approvals
Technological advancements in drug discovery that could outpace current capabilities
Increased competition from emerging biotech firms
Potential for larger pharmaceutical companies to internalize drug development processes
Negative operating cash flow impacting liquidity
Debt levels that could constrain future investments
moderate - Evotec's business is somewhat tied to the healthcare spending cycle, which can be influenced by broader economic conditions.
Higher interest rates could increase financing costs for ongoing research and development, potentially impacting profitability and valuation multiples.
minimal - Evotec's operations are not heavily reliant on credit markets.
growth - Investors are typically looking for companies with strong potential for revenue growth driven by innovative drug development.
high - The stock has shown significant price fluctuations, reflecting the inherent risks in the biotech sector.